The lifestyle layer that makes GLP-1 therapy work
Better adherence, preserved muscle and a supported off-ramp, with clinician sign-off and outcomes reported back to the payer.
Payers are spending heavily on GLP-1s and not keeping the results
members remain on GLP-1 treatment after three years
of large US employers rate managing GLP-1 costs as extremely or very important
after stopping, plus lean-muscle loss during treatment, with little structured support
Sources: Prime Therapeutics data, cited by Mercer, “GLP-1 considerations for 2026”; Mercer employer survey.
As drug prices fall, value moves to the program around the drug
Prices are falling
US agreements cut GLP-1 prices from over $1,000 to as low as $245 a month for eligible patients, and oral options are arriving.
Payers want lifestyle support
Employers and plans increasingly tie coverage to lifestyle and behavioral programs.
Medicare is paying for outcomes
The CMS ACCESS Model pays for technology-enabled care tied to outcomes in chronic conditions.
Sources: IQVIA, “Outlook for Obesity in 2026”; MedCity News, Jan 2026; AAMC on the CMS ACCESS Model.
One program across the whole GLP-1 journey
Baseline and onboarding
Body composition, activity, nutrition and gut-health baseline, plus a side-effect plan.
Adherence and muscle
Protein and strength targets, GI side-effect support and early flags for drop-off.
Supported step-down
A structured taper with the prescriber, and habits that hold results.
Activity comes from a wearable, the phone or a weekly check-in; nutrition and gut guidance from LIWEL’s own nutrition engine. A licensed clinician reviews and signs off every plan change. Prescribing stays with the member’s own clinician.
The payer sees what its GLP-1 spend is buying
| Outcome | What we measure | Why the payer cares |
|---|---|---|
| Adherence | Months on therapy; drop-off flags acted on | Value from each fill |
| Muscle preservation | Lean-mass trend, strength and activity | Healthier weight loss |
| Side effects | GI symptoms logged and resolved | Fewer early stops |
| Off-ramp | Weight held after step-down | Lower long-term drug cost |
Reported per cohort to the employer or plan, de-identified, each quarter. Outcome definitions and targets are agreed with each buyer.
Paid per member, with part of the fee tied to outcomes
Self-insured employers
A per-member-per-month fee, with a share at risk on adherence and outcomes.
Health plans, PBMs and obesity practices
The program as a condition of coverage, or white-labeled for prescribers.
Medicare and cash-pay members
Outcome-based Medicare models, and direct subscriptions.
We measure what keeps the results
Measured muscle preservation
Lean mass and strength are tracked, not just the scale.
Gut and side-effect support
Gut-health data and nutrition guidance help keep members on therapy.
A structured off-ramp
Step-down with the prescriber, monitored afterwards.
Clinician sign-off, one record
With or without a wearable: one record, and every change approved.
Signal, not noise, with or without a wearable
Ingest
Wearable, phone or check-in, meal logs and gut data.
Quality gate
Each source is scored for confidence; noise and gaps are dropped.
Personal baseline
Each member is compared to their own recent norm.
Fuse
Our nutrition engine, GI symptoms, weight and dose adherence.
Flag
Versioned rules give a plain-language flag and its reason.
Sign off, then learn
A clinician approves; outcomes tune the rules.
No device: meal logs, a weekly check-in, weight and clinic body composition. A phone adds steps; a wearable adds heart rate and sleep. Same flags, rising confidence.
Protein below target on 5 of 7 days, GI score up 2+ points and activity 30%+ below the member’s own baseline → a clinician reviews, with reasons and confidence.
Example thresholds are illustrative and are set and validated by our clinical team.
Two tracks to evidence in 2027
Employer pilot
A planned six-month pilot with a self-insured employer, for members on GLP-1 therapy.
Randomized study
Standard care vs LIWEL, with lean mass measured by DEXA, testing early-signal hypotheses.
Planned pilot readouts. LIWEL does not yet have US outcome results.
The people behind LIWEL
Neela
Serial founder with 20+ years of GCC leadership at Cisco, Juniper and Epicor.
Pankaja Shankar
Leads the core AI and predictive engine.
Giri Chenji
Former CTO, Immuneel; Deloitte Health (US).
Dr. Chithra Ram
Neuroradiologist with a fellowship in neuroradiology at Duke.
Let’s design a GLP-1 pilot together
We’re talking with self-insured employers and benefits consultants, obesity-medicine physicians, and health plans and PBMs.